Breaking News Instant updates and real-time market news.

CELG

Celgene

$98.50

-2.13 (-2.12%)

08:02
10/17/16
10/17
08:02
10/17/16
08:02

Celgene: Open-label Touchstone extension study showed symptom improvement

Celgene International Sarl announced that data from the open-label extension of the TOUCHSTONE phase 2 clinical trial of ozanimod in patients with moderate to severe ulcerative colitis are to be presented at the United European Gastroenterology Week in Vienna, Austria and at the American College of Gastroenterology Annual Scientific Meeting in Las Vegas. Ozanimod is an investigational selective S1P 1 and 5 receptor modulator. TOUCHSTONE evaluated the efficacy and safety of 0.5 mg and 1 mg doses of ozanimod compared with placebo after eight weeks of treatment in 197 patients with moderate to severe active ulcerative colitis. Patients who achieved a clinical response at week 8 continued with their original treatment through week 32 in a maintenance phase. The primary endpoint was the proportion of patients in remission at week 8. Secondary endpoints were: the proportion of patients achieving a clinical response, the proportion of patients with mucosal improvement and the change from baseline in Mayo score. Previously reported results showed TOUCHSTONE met its primary endpoint and secondary endpoints with statistical significance for patients on the 1 mg dose of ozanimod versus placebo. TOUCHSTONE participants in all three treatment arms entered the open-label extension if they did not respond to treatment after the induction phase, relapsed during the maintenance phase or completed the maintenance phase The objective of the open-label extension phase is to evaluate the long-term efficacy and safety of daily ozanimod 1 mg. Treatment with ozanimod 1 mg in the extension phase also showed a decrease in the proportion of patients with rectal bleeding and moderate or severe diarrhea. "Findings from this extension study at week 44 showed improvements in efficacy measures for patients who took ozanimod throughout both the blinded study and the extension," said Scott Smith, President, Celgene Inflammation & Immunology. "We recognize the strong need for innovative treatments that help patients with inflammatory bowel disease achieve durable results. We are committed to advancing additional transformational oral treatment options for these patients."

  • 27

    Oct

  • 06

    Nov

CELG Celgene
$98.50

-2.13 (-2.12%)

09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.
10/14/16
ADAM
10/14/16
NO CHANGE
Target $156
ADAM
Buy
Celgene pipeline broader and stronger than ever, says Canaccord
Canaccord analyst John Newman said Celgene's pipeline is broader and stronger than at any point in its history.He reiterated his Buy rating based on his confidence in the commercial potential for GED-0301 for Crohn's disease, ozanimod in both ulcerative colitis and multiple sclerosis, and continued growth for Otezla. Newman reiterated his $156 price target on Celgene shares.
10/17/16
WELS
10/17/16
NO CHANGE
WELS
Celgene data better than expected, says Wells Fargo
After Celgene announced detailed results from a phase 1b study of oral mogersen in moderate-to severe Crohn's Disease, Wells Fargo says that the results "are better than expected" and leave the company's drug "favorably" positioned relative to approved biologics. The firm says that Celgene's drug "could be positioned as the first highly effective oral for Crohn's Disease," and it keeps an Outperform rating on the stock.
10/17/16
LEER
10/17/16
NO CHANGE
LEER
Market Perform
Celgene data suggests viable drug, says Leerink
Leerink analyst Geoffrey Porges notes that Celgene has announced top-line results from Phase 1b study of GED-301 in Crohn's Disease, and says that absent statistical analyses or a greater insight into participant performance across the study's treatment arms, or longer duration of follow-up, it is difficult to evaluate the full significance of these results. Nonetheless, the analyst believes the drug seems to have some modest efficacy which bodes positively for potential approval as a front-line agent in Crohn's Disease. He reiterates a Market Perform rating on the shares.

TODAY'S FREE FLY STORIES

MOH

Molina Healthcare

$64.54

-0.78 (-1.19%)

, UNH

UnitedHealth

$191.75

-1.28 (-0.66%)

18:05
09/25/17
09/25
18:05
09/25/17
18:05
Hot Stocks
CBO: Graham-Cassidy ACA repeal bill to reduce number of insured by 'millions' »

The Congressional Budget…

MOH

Molina Healthcare

$64.54

-0.78 (-1.19%)

UNH

UnitedHealth

$191.75

-1.28 (-0.66%)

CNC

Centene

$90.33

-1.89 (-2.05%)

WCG

WellCare

$164.15

-3.01 (-1.80%)

CI

Cigna

$181.44

-1.3 (-0.71%)

ANTM

Anthem

$181.50

-1.36 (-0.74%)

HNT

Health Net

HUM

Humana

$237.21

-1.88 (-0.79%)

AET

Aetna

$151.98

-1.59 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

GPC

Genuine Parts

$93.22

5.24 (5.96%)

18:04
09/25/17
09/25
18:04
09/25/17
18:04
Recommendations
Genuine Parts analyst commentary  »

Genuine Parts acquisition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 19

    Oct

  • 30

    Oct

AA

Alcoa

$45.29

-0.09 (-0.20%)

, FCX

Freeport McMoRan

$13.89

-0.17 (-1.21%)

17:55
09/25/17
09/25
17:55
09/25/17
17:55
Recommendations
Alcoa, Freeport McMoRan, Teck Resources, Newmont Mining, Warrior Met Coal, Cleveland-Cliffs analyst commentary  »

Morgan Stanley raising…

AA

Alcoa

$45.29

-0.09 (-0.20%)

FCX

Freeport McMoRan

$13.89

-0.17 (-1.21%)

TECK

Teck Resources

$21.24

-0.72 (-3.28%)

NEM

Newmont Mining

$38.63

0.74 (1.95%)

HCC

Warrior Met Coal

$24.11

0.76 (3.25%)

CLF

Cleveland-Cliffs

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

  • 20

    Oct

  • 26

    Oct

17:55
09/25/17
09/25
17:55
09/25/17
17:55
Conference/Events
Federal Reserve Bank of Minneapolis President participates in a discussion »

Minneapolis Federal…

FTK

Flotek

$5.40

0.04 (0.75%)

17:49
09/25/17
09/25
17:49
09/25/17
17:49
Earnings
Flotek cuts Q3 revenue view by $5M, consensus $90.9M »

Flotek announced impacts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 14

    Nov

  • 16

    May

NBLX

Noble Midstream

$54.11

3.75 (7.45%)

17:44
09/25/17
09/25
17:44
09/25/17
17:44
Recommendations
Noble Midstream analyst commentary  »

Noble Midstream guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 31

    Oct

FB

Facebook

$162.87

-7.67 (-4.50%)

17:38
09/25/17
09/25
17:38
09/25/17
17:38
Periodicals
Russia looked to 'exploit' divisions in U.S. populace with Facebook ads, WP says »

The collection of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

ASNA

Ascena Retail

$2.17

0.07 (3.33%)

, SNX

Synnex

$116.50

0.4 (0.34%)

17:35
09/25/17
09/25
17:35
09/25/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Ascena…

ASNA

Ascena Retail

$2.17

0.07 (3.33%)

SNX

Synnex

$116.50

0.4 (0.34%)

RHT

Red Hat

$105.76

-0.54 (-0.51%)

ACTA

Actua

$12.25

-0.1 (-0.81%)

PRQR

ProQR Therapeutics

$6.45

0.25 (4.03%)

GNCA

Genocea

$5.33

0.04 (0.76%)

KDMN

Kadmon

$3.79

0.27 (7.67%)

QEP

QEP Resources

$8.88

0.51 (6.09%)

TXMD

TherapeuticsMD

$6.06

-0.11 (-1.78%)

BIOP

Bioptix

$4.11

-0.16 (-3.75%)

CSGP

CoStar Group

$279.20

-1.62 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 27

    Sep

  • 16

    Oct

  • 17

    Oct

  • 03

    Nov

  • 26

    Sep

GKOS

Glaukos

$31.26

-0.93 (-2.89%)

17:30
09/25/17
09/25
17:30
09/25/17
17:30
Hot Stocks
Breaking Hot Stocks news story on Glaukos »

James E. Flynn reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOP

Bioptix

$4.11

-0.16 (-3.75%)

17:28
09/25/17
09/25
17:28
09/25/17
17:28
Hot Stocks
Bioptix changes state of incorporation to Nevada from Colorado »

Bioptix said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$254.32

-2.13 (-0.83%)

17:26
09/25/17
09/25
17:26
09/25/17
17:26
Hot Stocks
Boeing and Qatar Airways announce order valued at $2.16B »

Boeing and Qatar Airways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CLXT

Calyxt

$26.54

0.82 (3.19%)

17:25
09/25/17
09/25
17:25
09/25/17
17:25
Hot Stocks
Calyxt: Herbicide-tolerant wheat, oil composition canola move to Phase 1 »

Calyxt announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MNK

Mallinckrodt

$35.25

0.42 (1.21%)

17:03
09/25/17
09/25
17:03
09/25/17
17:03
Earnings
Mallinckrodt sees InfaCare acquisition 15c-20c dilutive to FY17 adjusted EPS »

Mallinckrodt announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Oct

FTI

TechnipFMC

$27.02

0.19 (0.71%)

17:02
09/25/17
09/25
17:02
09/25/17
17:02
Hot Stocks
TechnipFMC implements share repurchase of up to $500M »

TechnipFMC announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

GNCA

Genocea

$5.33

0.04 (0.76%)

17:01
09/25/17
09/25
17:01
09/25/17
17:01
Hot Stocks
Breaking Hot Stocks news story on Genocea 

Genocea trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

TXMD

TherapeuticsMD

$6.06

-0.11 (-1.78%)

16:53
09/25/17
09/25
16:53
09/25/17
16:53
Syndicate
TherapeuticsMD files to sell 12.4M shares of common stock »

J.P. Morgan is acting as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 03

    Nov

LLL

L3 Technologies

$189.32

0.04 (0.02%)

16:52
09/25/17
09/25
16:52
09/25/17
16:52
Hot Stocks
L3 Technologies files protest with GAO related to Fort Rucker contract »

L3 Technologies announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRI

Apricus Biosciences

$1.73

0.05 (2.98%)

16:50
09/25/17
09/25
16:50
09/25/17
16:50
Syndicate
Apricus Biosciences requests withdrawal of registration statement »

The company confirms that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

CDXS

Codexis

16:48
09/25/17
09/25
16:48
09/25/17
16:48
Hot Stocks
Breaking Hot Stocks news story on Codexis »

Vivo Ventures lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 29

    Sep

  • 16

    Nov

AGRO

Adecogro

$10.05

-0.12 (-1.18%)

16:45
09/25/17
09/25
16:45
09/25/17
16:45
Hot Stocks
Adecoagro refinances majority of debt »

Adecoagro announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIBT

RiceBran

$1.21

-0.03 (-2.42%)

16:44
09/25/17
09/25
16:44
09/25/17
16:44
Hot Stocks
Breaking Hot Stocks news story on RiceBran »

Continental Grain reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Oct

CLDR

Cloudera

$16.08

-0.83 (-4.91%)

16:42
09/25/17
09/25
16:42
09/25/17
16:42
Syndicate
Cloudera announces 3M share follow-on offering »

Cloudera announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSGP

CoStar Group

$279.20

-1.62 (-0.58%)

16:38
09/25/17
09/25
16:38
09/25/17
16:38
Syndicate
CoStar Group announces $750M common stock offering »

CoStar expects to use the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

ENTL

Entellus Medical

$16.80

-0.89 (-5.03%)

16:36
09/25/17
09/25
16:36
09/25/17
16:36
Syndicate
Breaking Syndicate news story on Entellus Medical »

Entellus Medical files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STZ

Constellation Brands, also tag STZ.B

$200.61

-1.2 (-0.59%)

, STZ.B

Constellation Brands

16:36
09/25/17
09/25
16:36
09/25/17
16:36
Hot Stocks
Constellation Brands plans commercial paper program »

Constellation Brands…

STZ

Constellation Brands, also tag STZ.B

$200.61

-1.2 (-0.59%)

STZ.B

Constellation Brands

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.